months = 111, 60–144 months = 180. Severity classification: Mild intermittent=33, Mild persistent=61, Moderate persistent=181, Severe persistent=25. Children with persistent asthma received inhaled corticosteroid with (26%) or without (74%) long-acting-bronchodilator or Leukotriene-receptor-antagonist. Those with intermittent asthma received short course of bronchodilator. After 6mo, disease control could be assessed in 150 children who had at least 90% adherence to the prescribed treatment. Table 1 shows the distribution of demographic features, symptom profile, personal and family atopy, and exacerbating/triggering factors, in children with uncontrolled versus controlled disease.

Conclusion With the exception of night time symptoms at presentation, there are no specific features that can predict poor response to therapy in children with bronchial asthma.

PO-1023 OVER-PRESCRIPTION OF ADRENALINE AUTO-INJECTORS IN SCHOOL AGE CHILDREN?

G McCall, D Watkins, J Hughes. *Paediatrics, Antrim Hospital, Belfast, UK*

10.1136/archdischild-2014-307384.1639

Anaphylaxis is an acute, potentially life-threatening condition. Referral to specialist allergy services is vital to allow identification of triggers involved. One of the key purposes of these clinics is prescription of rescue medication, which can include adrenaline auto-injectors.

Aim We reviewed all patients who attended the Paediatric Allergy Clinic and were supplied with an adrenaline auto-injector over the period of January 2008–December 2013. We aimed to compare this number with the number of children with anaphylaxis care-plans in schools within the Northern Health and Social care trust.

Method We reviewed all submissions to the Adrenaline Auto-injector log-book. This is held at the Paediatric Allergy Clinic and completed each time a patient is seen who has been prescribed an adrenaline auto-injector. Information was obtained from the Public Health nursing team to ascertain the number of children with an anaphylaxis care-plan for school.

Results In 2013 there were 49,286 children aged between 5–16 years within the NHSC; 580 children were identified with an anaphylaxis care-plan held in school. Prevalence of school aged children at risk of anaphylaxis was 1.2%. Only 160 children (from birth to 18 years), with adrenaline auto-injector devices were reviewed at the allergy clinic in 2013, with 157 reviewed in 2012.

Between January 2008 and December 2013 there was six fold increase in patients seen at the Paediatric Allergy Clinic. We reviewed a total of 476 submissions to the Adrenaline Auto-injector logbook; 339 new patients and 137 review patients. There were no specific trends identified with regard to gender but there was a majority of patients under 5 yrs. There was a predominance of nut allergy in the new and review patients. Of the 68 new patients identified with an egg allergy 18% had a sole egg allergy, all of who had been prescribed an adrenaline auto-injector.

Conclusion There is a major shortfall with regard to the total number of children within the Northern HSCT who have been prescribed an adrenaline auto-injector and those who are seen at the Paediatric Allergy Clinic. This study has focused future efforts to review each of these patients in a formal paediatric allergy setting.

PO-1024 THE IMPORTANCE OF PROINFLAMMATORY CYTOKINE'S IN IMMUNE RESPONSE IN MYCOPLASMA PNEUMONIAE INFECTION IN CHILDREN WITH BRONCHOPULMONARY AFFECTATION

¹L Neamtu, ²O Tagadiuc, ¹S Sciuc. ¹Department of Pediatrics, State Medical and Pharmaceutical University, Chisinau, Moldova; ²Laboratory of Biochemistry, State Medical and Pharmaceutical University, Chisinau, Moldova

10.1136/archdischild-2014-307384.1640

Aims Our study was to evaluate proinflammatory cytokine's (IL-2) interaction with humoral immunity in children with *Mycoplasma pneumoniae* lower respiratory tract infection.

Methods The study group included 20 children, aged 5 months – 7 years, with pneumonia and wheezing induced by *Mycoplasma pneumoniae* infection. The diagnosis of *M.pneumoniae* was based on clinical, radiological and on the immunological determinations of specific antibodies in diagnosis titers. Levels of IgA, IgM, IgG, IL-2 were determined in serum samples obtained from all children and were tested by ELISA.

Results IL-2 levels in children with *Mycoplasma*-positive bronchopulmonary disease was $36,51 \pm 2,26$ pg/ml (variation 20,0–100,85 pg/ml) and it is higher, than in healthy children (variation 2,44–7,2 pg/ml) pg/ml. In study group average level of IgA was $0,96 \pm 0,13$ g/l did not differ from levels of IgA in healthy children ($0,9 \pm 0,04$ g/l). But level of serum IgM was higher ($p < 0,05$) in *Mp*-positive group ($1,8 \pm 0,16$ g/l) in comparison with levels of IgM in healthy children ($1,2 \pm 0,1$ g/l). In study group level of IgG was higher ($9,47 \pm 0,67$ g/l; $p < 0,05$) in comparison with age norms ($7,5 \pm 0,1$ g/l).

Conclusion Inflammatory processes in children with *Mycoplasma pneumoniae* infection are characterised by hyper production of IL-2, and they are associated with high serum levels of IgM, IgG.

PO-1025 PERSISTENT WHEEZING CASES AND TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN DURING INFANCY

O Özdemir, S Bozdoğan Polat. *Pediatric Allergy and Immunology, Sakarya University Medicine Faculty Research and Education Hospital, Sakarya, Turkey*

10.1136/archdischild-2014-307384.1641

Background When a physician comes across patients with recurrent wheezing are resistant to β_2 -agonist and anti-cholinergic therapy, known as atypical wheezing cases; he should investigate for hypogammaglobulinemia in these patients.

Aim Here, 3 cases are reported to make paediatricians aware of hypogammaglobulinemia, which is one of the reasons causing recurrent and persistent wheezing attacks during infancy and beyond.

Case presentations Case 1: 24 month-old girl presented to us with complaining of coughing and persistent wheezing. Her symptoms persisted even though she was using religiously nebulized salbutamol+budesonid therapy. Before this episode, she had 9 other wheezing attacks in her past medical history beginning from 2 months of age. Low IgG level (358 mg/dl) was detected at two different times. At the fourth day of admission, she was given IVIG 500mg/kg/dose. Case 2: 8-month-old girl came to our outpatient clinic with complaints of coughing and wheezing. Despite routine therapy, wheezing persisted for 2 months and wheezing severity increased and it did not respond to β_2 -agonist therapy. Low IgG level (304 mg/dl) was detected at two different times. At the 15th day of admission, she was